Navigation Links
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
Date:12/10/2008

or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at http://www.intermune.com.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)...  Kindred Hospital Houston Northwest, with Wound Care ... its new outpatient wound healing center.  The wound ... chronic, hard to heal wounds. Chronic wounds include ... lower leg wounds related to blood flow issues, ... injury wounds which are complex and demonstrate delayed ...
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery company, ... it has raised A$19.3 million via a placement of ... , the U.S., Asia ... from a share purchase plan (SPP) to be offered ... be made in two tranches. "This capital ...
(Date:7/11/2014)... July 11, 2014 On ... down 0.52%, the Dow Jones Industrial Average finished the day ... 1,964.68, down 0.41%. The losses were broad based as eight ... S&P 500 Health Care Sector Index ended the day at ... the last one month. Investor-Edge has initiated coverage on the ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
... is largely a collaborative enterprise. Frequently researchers from ... their efforts and exchange ideas, to devise new ... as those known as autism spectrum disorders, researchers ... diverse populations of patients, finding a broader pool ...
... AZOR Using 24-Hour Ambulatory BP MeasuresPARSIPPANY, N.J., May 8 ... at the American Society of Hypertension, Inc. (ASH) Twenty-Fourth ... Francisco from the AZ OR(R) T rial ... ontrol ( AZTEC ) demonstrated that a stepwise amlodipine ...
Cached Medicine Technology:Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 2Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 3Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 4New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 2New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 3New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 4New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 5New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 6New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 7New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 8New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 9
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Polio is history ... places like Afghanistan, Nigeria and Pakistan. Giving vaccinated children ... their immunity and help eradicate the highly infectious disease, ... is highly effective, immunity wanes as early as a ... be infected and contribute to the spread of the ...
(Date:7/11/2014)... breast cancer patients, the era of personalized medicine may ... by USC Stem Cell researcher Min Yu and scientists ... In a July 11 study in Science , ... cancer cells circulating through the blood streams of six ... "seeds" of metastasis, which travel to and establish secondary ...
(Date:7/11/2014)... FL (PRWEB) July 11, 2014 American ... on RFD-TV, next Tuesday, July 15, 2014, at 8:30 ... Sunbelt's line of proprietary products, which are designed and ... crops. Audiences will learn how these products help the ... environment in which it is grown. , The show ...
(Date:7/11/2014)... Shoulder instability is a common injury in ... has not been regularly determined following surgery. A new ... Medicine’s ( AOSSM ) Annual Meeting today details that ... no matter what the stabilization procedure (open vs. arthroscopic). ... to play following shoulder stabilization surgery. Age, number of ...
(Date:7/11/2014)... Anterior Cruciate Ligament (ACL) reconstructions occur more ... material used to create a new ligament may determine ... presenting their work today at the Annual Meeting of ... ). , “Our study results highlight that ... a donor) fail more frequently than using autografts (tissue ...
Breaking Medicine News(10 mins):Health News:Researchers Assess New Way to Boost Polio Immunity 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... , SINGAPORE, Nov. 16 /PRNewswire-Asia/ ... Malaysia grew steadily in the first half of 2009 with,total ... promotions from major Contact Lens manufacturers. Positive sales,data showing a ... view of an economic recovery that is being led by ...
... ... Critical Strategies for Successful Interactions Between Life Science Companies and Health Care Providers ... ... sales enablement and IT consulting company, today announced that UCB, a global biopharmaceutical ...
... ... Kids who Wear Ankle-Foot Orthoses (AFOs) , ... Westchester, NY (PRWEB) November 16, 2009 -- Ross Daniel Adaptive Apparel ... and the launch of “Cool Clothes for Toes,” the first creatively styled sock line for ...
... NANJING, China, Nov. 16 /PRNewswire-Asia/ -- Simcere Pharmaceutical ... pharmaceutical company,specializing in the development, manufacturing, and marketing of branded,generic and ... ended September 30, 2009. , , Highlights, ... the third, quarter of 2009, ...
... , Study highlights: , In patients with or ... treated with statins to < 100mg/dL but low HDL (good ... LDL further. , Patients were randomized to the addition of ... LDL cholesterol). Plaque buildup in the lining of the ...
... ... to begin the drug registration process in Brazil and Colombia for its over-the-counter pain ... for the treatment of moderate to severe (Stage 2) chronic pain. , ... Plantation, FL (Vocus) November 15, ...
Cached Medicine News:Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 3Health News:Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 12Health News:American Heart Association Late Breaking Clinical Trial Report: In Patients on Statins, Raising Good Cholesterol with Niacin, but not Reducing Bad Cholesterol with Ezetimibe, Decreases Plaque Build-Up 2Health News:American Heart Association Late Breaking Clinical Trial Report: In Patients on Statins, Raising Good Cholesterol with Niacin, but not Reducing Bad Cholesterol with Ezetimibe, Decreases Plaque Build-Up 3Health News:American Heart Association Late Breaking Clinical Trial Report: In Patients on Statins, Raising Good Cholesterol with Niacin, but not Reducing Bad Cholesterol with Ezetimibe, Decreases Plaque Build-Up 4Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 3Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 4
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
Medicine Products: